Markets:

Overview

News

Currencies

International

Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

85.01 +0.75 (+0.89%)

Official Closing Price Updated: 8:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Pharmaceutical ETF

< Previous 1 2 3 Next >

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Via Stocktwits

Topics World Trade

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗

November 15, 2025

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.

Via Benzinga

Topics ETFs

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗

September 26, 2025

Via Stocktwits

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Via Benzinga

Topics Government World Trade

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.

Via Benzinga

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.

Via Benzinga

Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗

July 28, 2025

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken...

Via Benzinga

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report ↗

July 11, 2025

FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.

Via Stocktwits

Topics Government

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Via Benzinga

FDA Aims To Reduce Drug Application Review Time With New Voucher Program ↗

June 17, 2025

The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final...

Via Stocktwits

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading ↗

June 10, 2025

A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.

Via Benzinga

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗

May 19, 2025

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.

Via Benzinga

Topics Government

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' ↗

May 11, 2025

Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.

Via Benzinga

Topics Government

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗

May 08, 2025

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

Via Benzinga

Topics ETFs Government

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and...

Via Stocktwits

Topics Government Intellectual Property Lawsuit

Trump Administration Considers Lowering US Drug Prices To International Levels: Report ↗

April 23, 2025

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

Via Benzinga

Topics Government

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Via Benzinga

Topics ETFs

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗

April 03, 2025

Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.

Via Benzinga

Topics World Trade

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

Topics ETFs Government World Trade

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.

Via Benzinga

US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget ↗

February 11, 2025

A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21.

Via Benzinga

Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery ↗

January 24, 2025

Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.

Via Benzinga

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗

December 19, 2024

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.